RAPT Therapeutics (RAPT) Price & Analysis

Compare

425 Followers

RAPT Stock Chart & Stats

$36.80

-$0.14(-8.75%)

At close: Jan 08 4:00 PM EST

$36.80

-$0.14(-8.75%)

Day’s Range― - ―

52-Week Range$5.67 - $42.39

Previous CloseN/A

Volume421.15K

Average Volume (3M)388.50K

Market Cap

$1.01B

Enterprise Value$540.63M

Total Cash (Recent Filing)$157.34M

Total Debt (Recent Filing)$2.60M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Mar 05, 2026

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding27,710,870

10 Day Avg. Volume391,280

30 Day Avg. Volume388,496

Financial Highlights & Ratios

PEG Ratio-0.86

Price to Book (P/B)2.71

Price to Sales (P/S)0.00

P/FCF Ratio-6.18

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-2.70K

Enterprise Value/Ebitda-5.01

Forecast

1Y Price Target

$64.38

Price Target Upside74.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-2.39

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessRAPT disclosed highly encouraging topline data from the Phase 2 trial of ozureprubart in chronic spontaneous urticaria.

Financial PositionFollowing the positive results, RAPT raised $250M in gross proceeds from a stock offering, which should help operations into mid-2028, including the initiation of a Phase 3 program with ozureprubart in CSU.

Regulatory ProgressThe FDA announced that one pivotal trial could be sufficient for approval for new therapies, which could accelerate timing for ozureprubart's path to market.

Bears Say

Financial PerformanceRAPT reported a net loss of $17.6M, or $0.65/share, in Q3 2025, compared to a net loss of $18.4M, or $3.79/share, in Q3 2024.

Trial LimitationsA less impactful second readout from Jeyou in asthma is expected, which is a smaller Phase 2a study not powered for efficacy endpoints.

RAPT Therapeutics News

Rapt Therapeutics participates in a conference call with H.C. Wainwright

Healthcare Analyst Bodnar holds a conference call with President & CEO Wong and CFO Young to discuss the...

9d ago

RAPT

RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on RAPT Therapeutics and keeping the price target...

8d ago

RAPT

RAPT Therapeutics Announces CMO Departure

RAPT Therapeutics ( ($RAPT) ) has issued an update. On November 24, 2025, RAPT Therapeutics announced that Chief...

15d ago

RAPT

Rapt Therapeutics price target raised to $57 from $55 at JPMorgan

JPMorgan raised the firm’s price target on Rapt Therapeutics (RAPT) to $57 from $55 and keeps an Overweight...

1M ago

RAPT

Rapt Therapeutics price target lowered to $56 from $58 at Barclays

Barclays lowered the firm’s price target on Rapt Therapeutics (RAPT) to $56 from $58 and keeps an Overweight...

1M ago

RAPT

RAPT Therapeutics Advances with Strong Financial Backing

Rapt Therapeutics Inc ( ($RAPT) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

RAPT

Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street

Clear Street views the shares of Rapt Therapeutics (RAPT) as “exceptionally compelling” following the company’s Q3 report. The...

1M ago

RAPT

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on RAPT Therapeutics. The associated price target...

1M ago

RAPT

Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on RAPT Therapeutics, retaining the price target of...

1M ago

RAPT

Rapt Therapeutics reports Q3 EPS (65c), consensus (85c)

“We have considerable momentum heading into the end of the year. We see tremendous potential for ozureprubart in...

1M ago

RAPT

Rapt Therapeutics price target raised to $72 from $48 at Wells Fargo

Wells Fargo raised the firm’s price target on Rapt Therapeutics (RAPT) to $72 from $48 and keeps an...

1M ago

RAPT

Rapt Therapeutics price target raised to $72 from $27 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Rapt Therapeutics (RAPT) to $72 from $27 and keeps a...

2M ago

RAPT

Clear Street positive on Rapt Therapeutics into food allergy study

Clear Street says Rapt Therapeutics (RAPT) announced a milestone by initiating its inaugural U.S. trial for ozureprubart in...

2M ago

RAPT

Rapt Therapeutics initiates prestIgE Phase 2b trial

RAPT Therapeutics (RAPT) announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of...

2M ago

RAPT

RAPT FAQ

What was RAPT Therapeutics’s price range in the past 12 months?

RAPT Therapeutics lowest stock price was $5.67 and its highest was $42.39 in the past 12 months.

What is RAPT Therapeutics’s market cap?

RAPT Therapeutics’s market cap is $1.01B.

When is RAPT Therapeutics’s upcoming earnings report date?

RAPT Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 82 days.

How were RAPT Therapeutics’s earnings last quarter?

RAPT Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.328.

Is RAPT Therapeutics overvalued?

According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does RAPT Therapeutics pay dividends?

RAPT Therapeutics does not currently pay dividends.

What is RAPT Therapeutics’s EPS estimate?

RAPT Therapeutics’s EPS estimate is -0.75.

How many shares outstanding does RAPT Therapeutics have?

RAPT Therapeutics has 27,710,870 shares outstanding.

What happened to RAPT Therapeutics’s price movement after its last earnings report?

RAPT Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went up 2.724%.

Which hedge fund is a major shareholder of RAPT Therapeutics?

Currently, no hedge funds are holding shares in RAPT

RAPT Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-85.37%

Trailing 12-Months

Asset Growth

52.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

RAPT Therapeutics

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Therapeutics (RAPT) Earnings & Revenues

Historic Earnings Reports

RAPT Stock 12 Month Forecast

Average Price Target

$64.38

▲(74.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","73":"$73","22.75":"$22.8","39.5":"$39.5","56.25":"$56.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$64.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,22.75,39.5,56.25,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,34.62461538461539,37.73923076923077,40.853846153846156,43.96846153846154,47.08307692307692,50.19769230769231,53.31230769230769,56.426923076923075,59.54153846153846,62.65615384615384,65.77076923076923,68.88538461538461,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,34.03846153846154,36.566923076923075,39.09538461538462,41.62384615384615,44.15230769230769,46.68076923076923,49.209230769230764,51.7376923076923,54.26615384615384,56.79461538461538,59.32307692307691,61.85153846153845,{"y":64.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.51,33.393846153846155,35.277692307692305,37.16153846153846,39.04538461538462,40.92923076923077,42.81307692307692,44.69692307692308,46.580769230769235,48.464615384615385,50.348461538461535,52.23230769230769,54.11615384615385,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.87,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >